Janet Yellen, chairman of the US Federal Reserve: Recent strong jobs numbers mean a December rate hike now looks a safe bet. Photograph: Joshua Roberts/Reuters

Investors have spent 2015 fretting as to whether the Federal Reserve would finally raise US interest rates and if so, when. Less attention has been pa(...)

Traders work on the floor of the New York Stock Exchange underneath a board showing the name of Valeant Pharmaceuticals shortly before the opening of the markets in New York October 22, 2015.  REUTERS/Lucas Jackson

Investors often say they learn more from investment losers than from winners. That suggests that Valeant, the beleaguered pharmaceutical company whose(...)

Valeant Pharmaceuticals, the Canadian drugmaker known for its serial acquisitions, reported first-quarter profit that topped analysts’ estimates and r(...)

Former Enron chairman Kenneth Lay: short-sellers tend to get a bad press but their defenders point to their exposure of questionable practices at companies like Enron. Photograph: Dave Einsel/Getty Images

Short-sellers profit from market declines, something that has long ensured their unpopularity with politicians, regulators and chief executives. Napol(...)

Traders  on the floor of the New York Stock Exchange. Photograph: Jewel Samad/AFP/Getty Images

Volatility, it appears, is back. After two years of remarkable calm, investor jitters have returned. It’s not simply that stocks are declining; there (...)

Botox is one of a number of pharmaceutical products made in Allergan’s Westport plant. Photograph: Shannon Stapleton/Files/Reuters

Allergan, the maker of Botox, has agreed to sell itself in a $66 billion (€53 billion) deal with fellow drugs group Actavis, with rival Valeant bowing(...)

Valeant had said it was willing to pay at least $200 a share and has the backing of Allergan’s largest shareholder -- activist investor Bill Ackman’s (pictured) Pershing Square Capital Management LP. ( Photograph: Scott Eells/Bloomberg)

Actavis has agreed to pay about $66 billion (€52.6bn) for Allergan, after the maker of Botox turned to the drugmaker to repel a hostile advance from V(...)

In London, supermarket giant Tesco was back under pressure with a decline of nearly 3 per cent or 4.6p to 180.6p. Photograph: Rui Vieira/PA Wire.

European stocks were little changed today as investors signalled they are likely to hold fire until they see stronger signs of a recovery. Values slu(...)


Correction or not, investors may need to “buckle up for more volatility” following the recent “market rout”, Blackrock recently cautioned. Two (...)

Valeant Pharmaceuticals  offered to buy Allergan, maker of the Botox wrinkle treatment, in a cash-and-stock deal valued at $45.7 billion in the latest step of the Canadian company’s plan to become one of the world’s largest drugmakers. Photographer: Patrick T. Fallon/Bloomberg

Valeant Pharmaceuticals said it began an exchange offer for Botox maker Allergan, taking its hostile $50.8 billion bid directly to shareholders. Que(...)